Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05984147 | A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1) | PHASE1 | RECRUITING | 40 | — | — | Oct 19, 2023 | Aug 30, 2027 | Apr 17, 2026 | 27 | India |
Assess dose limiliting toxicities of AUR108
Number of participants with TEAEs
Maximum Concentration of AUR108
Tmax in hours
Area under the curve (AUC) of AUR108 in h\* ng/mL
Terminal elimination half-life of AUR 108 in hours
Compare in fast and fed conditions
Compare Tmax in fast and fed conditions
Compare AUC in fast and fed conditions
| Arm | Type | Description |
|---|---|---|
| AUR108, 50mg to 300mg | EXPERIMENTAL | Currently, planned dose levels are 50,90,150,220,300 mg will be administered in 3+/4- regimen. |
| Name | Type | Description |
|---|---|---|
| AUR108 | DRUG | 3 Days dosing, and 4 days no dose in a week |
Inclusion Criteria: 1. Males or females ≥ 18 years of age 2. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 3. Acceptable bone marrow and organ function at screening as described below: 1. ANC ≥ 1000/μL (without WBC growth factor support) 2. Platelet count ≥ 75,000/μL...